n/a
Article Publish Status: FREE
Abstract Title:

Andrographolide Suppresses Pyroptosis inMacrophages via the microRNA-155/Nrf2 Axis.

Abstract Source:

Oxid Med Cell Longev. 2022 ;2022:1885066. Epub 2022 Apr 28. PMID: 35528511

Abstract Author(s):

Yan Fu, Jingjing Shen, Fanglin Liu, Hemin Zhang, Yuejuan Zheng, Xin Jiang

Article Affiliation:

Yan Fu

Abstract:

Tuberculosis (TB) remains a leading threat to public health worldwide with(Mtb) infections causing long-term abnormal and excessive inflammatory responses, which in turn lead to lung damage and fibrosis, and ultimately death. Host-directed therapy (HDT) has been shown to be an effective anti-TB strategy in the absence of effective anti-TB drugs. Here, we used anmacrophage model of Mtb infection to evaluate the effects of andrographolide (Andro), extracted from, on pyroptosis in Mtb-infected macrophages. We evaluated the molecular mechanisms underlying these outcomes. These evaluations revealed that Andro downregulated the expression of proinflammatory miR-155-5p, which then promoted the expression of Nrf2 to suppress pyroptosis in Mtb-infected macrophages. Further study also demonstrated that siNrf2 could attenuate the inhibitory effect of Andro on TXNIP, validating our mechanistic studies. Thus, our data suggest that Andro may be a potential candidate adjuvant drug for anti-TB therapy as it inhibits pyroptosis in Mtb-infected macrophages, potentially improving clinical outcomes.

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.